Drug firm AstraZeneca India on Friday said it has received approval from the domestic drug regulator to market a drug to treat biliary tract cancer (BTC) in the country. The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Durvalumab, the drug firm said in a statement.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fZmHGT3
via IFTTT
0 comments:
Post a Comment